|
Prevention of Opportunistic Infections Other than Mycobacterium avium Complex (MAC) in a Randomized, Placebo-Controlled Trial of Azithromycin (AZ) Prophylaxis in Subjects with Increases in CD4 Cells on Antiretroviral Therapy (ART) - Preliminary Results S. L. KOLETAR1 *, J. S. CURRIER2, P. L. WILLIAMS3, R. HAFNER4, R. L. MURPHY5, S. COHN6, C. KNIRSCH7, T. NEVIN8, and J. A. MCCUTHCHAN9 for the ACTG 362 TEAM. 1Ohio State Univ., Columbus; 2Univ. of California Los Angeles; 3Harvard Sch. of Publ. Hlth., Boston, MA; 4NIAID, Bethesda, MD; 5Northwestern Univ., Chicago, IL; 6Univ. of Rochester, NY; 7Pfizer, New York, NY; 8AACTG Operations Ctr., Rockville, MD; and 9Univ. of California, San Diego
Background: Recent reports suggest that specific prophylaxis for
MAC can be safely discontinued in patients (pts) who sustain ART-induced
increases in CD4 counts. Whether this benefit extends to other opportunistic
infections is less clear. There were 10 deaths (3 AZ, 7 placebo). Differences in infections
and deaths were not statistically different between groups. Key Words: azithromycin, bacterial infections, prophylaxis |
|
© 7th
Conference on Retroviruses and Opportunistic Infections, |